Developer docs
API playgroundTry for free, no card

Search company profiles

QuantaMatrix

Full company profile

uuid000ffhn

Namestring
QuantaMatrix
Legal namestring
QuantaMatrix Inc.
Company typeenum
Public
Founded yearint
2010
Descriptiontext

QuantaMatrix is a South Korea-headquartered in-vitro diagnostics company, founded in 2010 as a spin-off from Seoul National University's Biophotonics and Nano Engineering Lab, that develops rapid diagnostic platforms for infectious disease and disease screening applications. The company's technology stack is built on two proprietary platforms: a Microfluidic Agarose Channel (MAC) system combined with time-lapse microscopic imaging for phenotypic antimicrobial susceptibility testing, and a QuantaMatrix Multiplex Assay Platform (QMAP) using coded Microdisk microparticles for simultaneous multi-biomarker detection. Its commercial product portfolio centers on dRAST, which delivers MIC-based antimicrobial susceptibility results from positive blood cultures in as few as 4 hours versus 2-3 days for conventional methods; QDST for tuberculosis drug susceptibility testing in 7 days; QPLEX Alz plus for blood-based early Alzheimer's diagnosis; Quanti9 and QuantiGal for cardiovascular risk prediction; and uRAST, a next-generation system published in Nature in August 2024 that produces results within 13 hours directly from blood samples.

QuantaMatrix generates revenue through a hybrid model combining capital equipment sales of automated diagnostic instruments (dRAST, QDST, QMIA) with recurring consumables revenue from proprietary test kit panels, agarose, and broth. The company sells directly to hospital clinical microbiology laboratories through enterprise field sales and through a distribution network covering 26 countries across Europe and the Middle East, with named channel partners including Argenta (Poland), Neo-Science (UAE), and Limbach Group (Germany), plus inclusion in the UniHA French hospital purchasing consortium catalog. QuantaMatrix has been publicly listed on the Korean KOSDAQ exchange under ticker A317690 since December 2020, when it raised $40.2 million USD at its IPO, and most recently received a $2.85 million USD CARB-X grant in August 2025 to develop a neonatal sepsis diagnostic platform. The company maintains its headquarters in Seoul, a European subsidiary office in Villejuif, France, and an R&D presence at Seoul National University Hospital.

Short descriptiontext

QuantaMatrix is a Seoul-based in-vitro diagnostics company that builds microfluidic and multiplex assay platforms to deliver rapid antimicrobial susceptibility testing and multi-marker disease screening for hospital clinical microbiology laboratories across 26 countries in Europe and the Middle East.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
in-vitro diagnostics, rapid antimicrobial susceptibility testing, microfluidic diagnostic platforms, sepsis diagnostics, clinical microbiology automation
Industry4 codes
PRIMARYHLAAALAC
Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)
SECONDARYHLAGAIAE
Microscopy, Imaging & Flow Cytometry Instruments
SECONDARYHLAHAAAC
Microbiology & Infectious Disease Diagnostics (Culture/ID/AST)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
In-vitro Diagnostics (Clinical Microbiology)
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Diagnostic Systems and Consumables
TypeHardware Sales
Description

Sale of automated diagnostic instruments (dRAST, QDST, QMIA) along with proprietary test kits and consumables including panels, agarose, and broth. Revenue generated from capital equipment sales and recurring consumable revenue from test kit purchases.

quantamatrix.com
2Diagnostic Testing Kits
TypeOne Time License
Description

Proprietary test kits for antimicrobial susceptibility testing (dRAST panels, QDST panels) and disease detection (QPLEX, Quanti9/QuantiGal). Consumables revenue from hospitals and laboratories performing tests.

quantamatrix.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1dRAST
Description

Direct & Rapid Antimicrobial Susceptibility Testing system providing MIC-based phenotypic AST results in as low as 4 hours from positive blood cultures.

quantamatrix.com
+6 more records
Core offering1 text field

QuantaMatrix develops and commercializes rapid in-vitro diagnostic systems for clinical microbiology, with flagship applications in bloodstream infection/sepsis antimicrobial susceptibility testing (dRAST), tuberculosis drug susceptibility testing (QDST), Alzheimer's disease screening (QPLEX Alz plus), and cardiovascular diagnostics (Quanti9 and QuantiGal). Its portfolio combines proprietary microfluidic agarose channel hardware, time-lapse imaging software, and multiplex immunoassays, sold as integrated instruments plus consumables to hospital laboratories and reference centers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • dRAST reduces AST turnaround from 64.5 hours (conventional) to 14.3 hours average; time to optimal treatment decreased by 14 hours (39.0 hrs vs 53.2 hrs)
+5 more records
Product overview1 text field

QuantaMatrix is an in-vitro diagnostics company offering a portfolio of rapid diagnostic solutions built on its proprietary microfluidic and multi-marker technology platforms. The product portfolio centers on two core platforms — the MAC (Microfluidic Agarose Channel) technology for phenotypic antimicrobial susceptibility testing, and the QMAP (QuantaMatrix Multiplex Assay Platform) using coded Microdisk technology for multi-marker immunoassay detection. The lead product, dRAST (direct & Rapid Antimicrobial Susceptibility Test), provides MIC-based AST results directly from positive blood cultures in as little as 4 hours via microfluidic agarose channel and time-lapse microscopic imaging, with 2 panels (Gram-negative and Gram-positive) supporting CLSI and EUCAST guidelines. QDST delivers TB drug susceptibility results in 7 days using the same MAC technology with enhanced biosafety. The QMAP-based QPLEX Alz plus assay detects 4 Alzheimer's disease biomarkers from blood plasma via the automated QMIA system, and the ELISA-based Quanti9 & QuantiGal kits predict heart failure risk from cardiovascular biomarkers. The next-generation uRAST eliminates blood culture entirely, producing results in 13 hours with a 94.9% accuracy rate, and QMAP One-pot Assay targets neonatal sepsis with 6-hour turnaround from minimal blood volumes.

Product and service1 record
1dRAST
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Seoul National University Hospital
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-08-19
Description

Clinical validation partner for uRAST technology testing. Hospital conducted validation studies demonstrating uRAST reduced time from positive blood culture to optimal antimicrobial prescription by average of 13 hours compared to conventional methods. Published results in Nature journal.

quantamatrix.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-10-30
Description

Polish distribution partner for dRAST sepsis solution. Partnered with QuantaMatrix to secure WOŚP sepsis tender, supplying 20 dRAST units to Polish hospitals and healthcare institutions. Argenta provides sales, clinical education, and after-sales service support in Poland.

Strategic tierFlagshipTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-09-04
Description

Union of Hospitals for Purchasing - French hospital purchasing consortium. dRAST has been integrated and validated into UniHA's product catalog, enabling simplified procurement of the diagnostic system for member hospitals across France.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-02-21
Description

Distribution partnership for UAE market covering the Middle East region. Neo-Science serves as the authorized distributor for QuantaMatrix products in the United Arab Emirates, expanding the company's presence in the Middle East and Africa region.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-12-15
Description

German laboratory group that adopted QuantaMatrix's dRAST in routine clinical use. Represents implementation of dRAST technology in European healthcare system, demonstrating adoption by major laboratory network.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1bioM\u00e9rieux
TypeDirect peer
Description

Global leader in clinical microbiology diagnostics with the VITEK 2 AST platform, which competes head-to-head with QuantaMatrix dRAST/uRAST in hospital laboratories. Direct overlap in phenotypic antimicrobial susceptibility testing and sepsis workflows.

TypeDirect peer
Description

Commercializes the Accelerate Pheno system, a rapid phenotypic AST platform delivering results in hours from positive blood cultures. Most direct competing technology stack and customer segment to QuantaMatrix dRAST.

TypeBroad incumbent
Description

Major incumbent in clinical microbiology and hospital-acquired infection diagnostics through BD MAX and BD Phoenix AST systems. Overlaps with QuantaMatrix on hospital microbiology customers and antimicrobial stewardship positioning.

TypeBroad incumbent
Description

Operates the MALDI Biotyper for microbial ID and is expanding into AST via the MBT-ASTRA workflow. Competes on the same hospital bloodstream infection pathway as QuantaMatrix dRAST/uRAST, often as the upstream ID step.

5Beckman Coulter (Danaher)
TypeBroad incumbent
Description

Supplies the MicroScan AST platform used widely in hospital microbiology labs. Overlaps with QuantaMatrix's hospital clinical microbiology customer base and antimicrobial susceptibility reporting workflows.

TypeBroad incumbent
Description

GeneXpert system is the dominant rapid molecular TB testing platform with integrated DST. Competes with QuantaMatrix QDST for TB drug susceptibility throughput in reference laboratories.

TypeEmerging player
Description

Develops T2 Magnetic Resonance-based direct-from-blood pathogen detection for bloodstream infections. Adjacent emerging technology targeting the same sepsis use case as uRAST but using molecular rather than phenotypic methodology.

8Qvella Corporation
TypeEmerging player
Description

Developer of the FAST ID/AST system for rapid direct-from-sample bloodstream infection testing. Early-stage competitor pursuing a similar culture-free AST workflow as uRAST.

TypeEmerging player
Description

Developer of the Next-Generation Phenotyping (NGP) AST platform aimed at delivering rapid phenotypic AST directly from positive blood cultures. Direct emerging competitor to dRAST in the rapid AST category.

TypeBroad incumbent
Description

Broad IVD incumbent offering cobas blood culture and AST solutions plus Alzheimer's CSF biomarker assays (Elecsys). Competes with QuantaMatrix in the same hospital lab purchasing decisions across multiple indications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

QuantaMatrix

In-vitro Diagnostics (Clinical Microbiology)quantamatrix.com

QuantaMatrix is a Seoul-based in-vitro diagnostics company that builds microfluidic and multiplex assay platforms to deliver rapid antimicrobial susceptibility testing and multi-marker disease screening for hospital clinical microbiology laboratories across 26 countries in Europe and the Middle East.

What QuantaMatrix does

QuantaMatrix is a South Korea-headquartered in-vitro diagnostics company, founded in 2010 as a spin-off from Seoul National University's Biophotonics and Nano Engineering Lab, that develops rapid diagnostic platforms for infectious disease and disease screening applications. The company's technology stack is built on two proprietary platforms: a Microfluidic Agarose Channel (MAC) system combined with time-lapse microscopic imaging for phenotypic antimicrobial susceptibility testing, and a QuantaMatrix Multiplex Assay Platform (QMAP) using coded Microdisk microparticles for simultaneous multi-biomarker detection. Its commercial product portfolio centers on dRAST, which delivers MIC-based antimicrobial susceptibility results from positive blood cultures in as few as 4 hours versus 2-3 days for conventional methods; QDST for tuberculosis drug susceptibility testing in 7 days; QPLEX Alz plus for blood-based early Alzheimer's diagnosis; Quanti9 and QuantiGal for cardiovascular risk prediction; and uRAST, a next-generation system published in Nature in August 2024 that produces results within 13 hours directly from blood samples.

QuantaMatrix generates revenue through a hybrid model combining capital equipment sales of automated diagnostic instruments (dRAST, QDST, QMIA) with recurring consumables revenue from proprietary test kit panels, agarose, and broth. The company sells directly to hospital clinical microbiology laboratories through enterprise field sales and through a distribution network covering 26 countries across Europe and the Middle East, with named channel partners including Argenta (Poland), Neo-Science (UAE), and Limbach Group (Germany), plus inclusion in the UniHA French hospital purchasing consortium catalog. QuantaMatrix has been publicly listed on the Korean KOSDAQ exchange under ticker A317690 since December 2020, when it raised $40.2 million USD at its IPO, and most recently received a $2.85 million USD CARB-X grant in August 2025 to develop a neonatal sepsis diagnostic platform. The company maintains its headquarters in Seoul, a European subsidiary office in Villejuif, France, and an R&D presence at Seoul National University Hospital.

QuantaMatrix firmographics

Firmographics
Name
QuantaMatrix
Legal name
QuantaMatrix Inc.
Website
https://quantamatrix.com
Company type
Public
Founded year
2010
Operating status
Operating
Headcount range
51–100 employees
Short description
QuantaMatrix is a Seoul-based in-vitro diagnostics company that builds microfluidic and multiplex assay platforms to deliver rapid antimicrobial susceptibility testing and multi-marker disease screening for hospital clinical microbiology laboratories across 26 countries in Europe and the Middle East.
Ownership category
akta.pro rank

QuantaMatrix industry classification

Industry
Product category
In-vitro Diagnostics (Clinical Microbiology)
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAALAC
Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)
SECONDARYHLAGAIAE
Microscopy, Imaging & Flow Cytometry Instruments
SECONDARYHLAHAAAC
Microbiology & Infectious Disease Diagnostics (Culture/ID/AST)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)

Keywords

  • In-vitro diagnostics
  • Rapid antimicrobial susceptibility testing
  • Microfluidic diagnostic platforms
  • Sepsis diagnostics
  • Clinical microbiology automation

Where QuantaMatrix is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices4 records

Markets served

QuantaMatrix business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Diagnostic Systems and Consumables: Sale of automated diagnostic instruments (dRAST, QDST, QMIA) along with proprietary test kits and consumables including panels, agarose, and broth. Revenue generated from capital equipment sales and recurring consumable revenue from test kit purchases.
  2. Diagnostic Testing Kits: Proprietary test kits for antimicrobial susceptibility testing (dRAST panels, QDST panels) and disease detection (QPLEX, Quanti9/QuantiGal). Consumables revenue from hospitals and laboratories performing tests.

Go-to-market motion3 records

Distribution channels6 records

Marketing channels8 records

QuantaMatrix product offering

Product offering

Core offering

QuantaMatrix develops and commercializes rapid in-vitro diagnostic systems for clinical microbiology, with flagship applications in bloodstream infection/sepsis antimicrobial susceptibility testing (dRAST), tuberculosis drug susceptibility testing (QDST), Alzheimer's disease screening (QPLEX Alz plus), and cardiovascular diagnostics (Quanti9 and QuantiGal). Its portfolio combines proprietary microfluidic agarose channel hardware, time-lapse imaging software, and multiplex immunoassays, sold as integrated instruments plus consumables to hospital laboratories and reference centers.

Product overview

QuantaMatrix is an in-vitro diagnostics company offering a portfolio of rapid diagnostic solutions built on its proprietary microfluidic and multi-marker technology platforms. The product portfolio centers on two core platforms — the MAC (Microfluidic Agarose Channel) technology for phenotypic antimicrobial susceptibility testing, and the QMAP (QuantaMatrix Multiplex Assay Platform) using coded Microdisk technology for multi-marker immunoassay detection. The lead product, dRAST (direct & Rapid Antimicrobial Susceptibility Test), provides MIC-based AST results directly from positive blood cultures in as little as 4 hours via microfluidic agarose channel and time-lapse microscopic imaging, with 2 panels (Gram-negative and Gram-positive) supporting CLSI and EUCAST guidelines. QDST delivers TB drug susceptibility results in 7 days using the same MAC technology with enhanced biosafety. The QMAP-based QPLEX Alz plus assay detects 4 Alzheimer's disease biomarkers from blood plasma via the automated QMIA system, and the ELISA-based Quanti9 & QuantiGal kits predict heart failure risk from cardiovascular biomarkers. The next-generation uRAST eliminates blood culture entirely, producing results in 13 hours with a 94.9% accuracy rate, and QMAP One-pot Assay targets neonatal sepsis with 6-hour turnaround from minimal blood volumes.

Differentiator

Problem solved

Functional benefit

Brands

  • dRAST: Direct & Rapid Antimicrobial Susceptibility Testing system providing MIC-based phenotypic AST results in as low as 4 hours from positive blood cultures.
  • QDST
  • QMAP
  • QMIA
  • QMAP 2.0
  • Quanti9
  • QuantiGal

Products and services

  • dRAST

Quantifiable outcome

  • dRAST reduces AST turnaround from 64.5 hours (conventional) to 14.3 hours average; time to optimal treatment decreased by 14 hours (39.0 hrs vs 53.2 hrs)
  • +5 more outcomes

Companies that use QuantaMatrix

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles1 record

QuantaMatrix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability5 records

Feature6 records

QuantaMatrix partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and flagship.

  • Seoul National University HospitalcoreStrategic or Co-development Partner · 19 August 2024Clinical validation partner for uRAST technology testing. Hospital conducted validation studies demonstrating uRAST reduced time from positive blood culture to optimal antimicrobial prescription by average of 13 hours compared to conventional methods. Published results in Nature journal.
  • Argenta Sp. z o.o.coreChannel Partner/ Reseller/ Distributor · 30 October 2023Polish distribution partner for dRAST sepsis solution. Partnered with QuantaMatrix to secure WOŚP sepsis tender, supplying 20 dRAST units to Polish hospitals and healthcare institutions. Argenta provides sales, clinical education, and after-sales service support in Poland.
  • UniHAflagshipChannel Partner/ Reseller/ Distributor · 4 September 2023Union of Hospitals for Purchasing - French hospital purchasing consortium. dRAST has been integrated and validated into UniHA's product catalog, enabling simplified procurement of the diagnostic system for member hospitals across France.
  • Neo-SciencecoreChannel Partner/ Reseller/ Distributor · 21 February 2023Distribution partnership for UAE market covering the Middle East region. Neo-Science serves as the authorized distributor for QuantaMatrix products in the United Arab Emirates, expanding the company's presence in the Middle East and Africa region.
  • Limbach GroupcoreChannel Partner/ Reseller/ Distributor · 15 December 2021German laboratory group that adopted QuantaMatrix's dRAST in routine clinical use. Represents implementation of dRAST technology in European healthcare system, demonstrating adoption by major laboratory network.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

QuantaMatrix competitors and assessment

Company assessment

Direct peers

  • bioM\u00e9rieux: Global leader in clinical microbiology diagnostics with the VITEK 2 AST platform, which competes head-to-head with QuantaMatrix dRAST/uRAST in hospital laboratories. Direct overlap in phenotypic antimicrobial susceptibility testing and sepsis workflows.
  • Accelerate Diagnostics: Commercializes the Accelerate Pheno system, a rapid phenotypic AST platform delivering results in hours from positive blood cultures. Most direct competing technology stack and customer segment to QuantaMatrix dRAST.

Broad incumbents

  • Becton Dickinson (BD): Major incumbent in clinical microbiology and hospital-acquired infection diagnostics through BD MAX and BD Phoenix AST systems. Overlaps with QuantaMatrix on hospital microbiology customers and antimicrobial stewardship positioning.
  • Bruker Corporation: Operates the MALDI Biotyper for microbial ID and is expanding into AST via the MBT-ASTRA workflow. Competes on the same hospital bloodstream infection pathway as QuantaMatrix dRAST/uRAST, often as the upstream ID step.
  • Beckman Coulter (Danaher): Supplies the MicroScan AST platform used widely in hospital microbiology labs. Overlaps with QuantaMatrix's hospital clinical microbiology customer base and antimicrobial susceptibility reporting workflows.
  • Cepheid (Danaher): GeneXpert system is the dominant rapid molecular TB testing platform with integrated DST. Competes with QuantaMatrix QDST for TB drug susceptibility throughput in reference laboratories.
  • Roche Diagnostics: Broad IVD incumbent offering cobas blood culture and AST solutions plus Alzheimer's CSF biomarker assays (Elecsys). Competes with QuantaMatrix in the same hospital lab purchasing decisions across multiple indications.

Emerging players

  • T2 Biosystems: Develops T2 Magnetic Resonance-based direct-from-blood pathogen detection for bloodstream infections. Adjacent emerging technology targeting the same sepsis use case as uRAST but using molecular rather than phenotypic methodology.
  • Qvella Corporation: Developer of the FAST ID/AST system for rapid direct-from-sample bloodstream infection testing. Early-stage competitor pursuing a similar culture-free AST workflow as uRAST.
  • Selux Diagnostics: Developer of the Next-Generation Phenotyping (NGP) AST platform aimed at delivering rapid phenotypic AST directly from positive blood cultures. Direct emerging competitor to dRAST in the rapid AST category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

QuantaMatrix social profiles

Digital presence

QuantaMatrix compliance and trust

Trust signal

Compliance2 records

QuantaMatrix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

QuantaMatrix leadership team

Management profile

Number of profiles

QuantaMatrix funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

QuantaMatrix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about QuantaMatrix

What does QuantaMatrix do?

QuantaMatrix develops and commercializes rapid in-vitro diagnostic systems for clinical microbiology, with flagship applications in bloodstream infection/sepsis antimicrobial susceptibility testing (dRAST), tuberculosis drug susceptibility testing (QDST), Alzheimer's disease screening (QPLEX Alz plus), and cardiovascular diagnostics (Quanti9 and QuantiGal). Its portfolio combines proprietary microfluidic agarose channel hardware, time-lapse imaging software, and multiplex immunoassays, sold as integrated instruments plus consumables to hospital laboratories and reference centers.

Is QuantaMatrix a public or private company?

QuantaMatrix is a public company. It is classified as public and is currently operating.

When was QuantaMatrix founded?

QuantaMatrix was founded in 2010. It employs 51 to 100 people.

Where is QuantaMatrix based?

QuantaMatrix is headquartered in Seoul, South Korea, in the Asia region.

How does QuantaMatrix make money?

Two revenue lines are on record. Diagnostic Systems and Consumables are the primary driver. The others are diagnostic Testing Kits.

Who are QuantaMatrix's main competitors?

Direct peers on record are bioM\u00e9rieux and Accelerate Diagnostics. Broad incumbents are Becton Dickinson (BD), Bruker Corporation, Beckman Coulter (Danaher), Cepheid (Danaher) and Roche Diagnostics. Emerging players are T2 Biosystems, Qvella Corporation and Selux Diagnostics.

Does QuantaMatrix have an API?

No public API is recorded for QuantaMatrix.

What industry is QuantaMatrix in?

QuantaMatrix's product category is In-vitro Diagnostics (Clinical Microbiology). Its primary akta.pro industry code is HLAAALAC, Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels), with a secondary code of HLAGAIAE, Microscopy, Imaging & Flow Cytometry Instruments. Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceadmed laboratory adopts QuantaMatrix dRAST solution in routine clinical useQuantaMatrix announced that its dRAST solution is now in routine clinical use at admed, a Swiss laboratory. The system cuts antibiotic susceptibility testing time by two days, enabling same-day results for positive blood cultures. This is the sixth application, following adoption in five other labs.PR NewswireLimbach Group adopts QuantaMatrix dRAST™ in routine clinical useQuantaMatrix's dRAST platform has been adopted for routine clinical use by the Limbach Group, Germany's largest owner-managed laboratory group, following successful validation by major European reference laboratories. The deployment, facilitated through a partnership between QuantaMatrix Europe and Axonlab, enables sepsis patients to receive optimal antibiotic prescriptions approximately two days faster than conventional methods. QuantaMatrix, a Korean in vitro diagnostics company listed on KOSDAQ, is expanding its European footprint across Germany, Switzerland, Austria, and Benelux after establishing a distribution network spanning 24 EMEA countries.PR NewswireQuantaMatrix to Debut on KOSDAQ on Wednesday (12/9) after raising $40.2mn in IPO, at $23.57QuantaMatrix, a South Korean in-vitro diagnostics company specializing in sepsis management, successfully listed on KOSDAQ on December 9, 2020, raising $40.2 million through its IPO priced at $23.57 per share, the top of its price band, implying a market capitalization of approximately $344 million. The offering drew 699 institutional investors with orders oversubscribed by more than 185 times, reflecting strong market demand. The company plans to use the proceeds to fund R&D, expand its European subsidiary, and pursue global market entry including the United States.The Korea Herald[Herald Interview] QuantaMatrix seeks October IPO for overseas entryQuantaMatrix, a microbial diagnostic developer, plans an IPO on Korea's Kosdaq next month, aiming to raise up to 85.34 billion won ($71.8 million). Its dRAST test cuts sepsis testing time by 30-50 hours, and the company seeks FDA approval by 2022. Proceeds will fund overseas expansion, including the US and China.